용량에 따른 유리체강내 트리암시놀론 주입과 베바시주맙 주입이 안압에 미치는 영향
The Effect of Intravitreal Triamcinolone Acetonide and Bevacizumab Injection on Intraocular Pressure
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
목적: 유리체강내 트리암시놀론주입술과 베바시주맙주입술 후 용량에 따른 안압의 변화를 비교하였다. 대상과 방법: 유리체강내 트리암시놀론 0.1 ml를 주입받은 40명과 베바시주맙 0.05 ml 주입술 후 0.1 ml를 재주입받은 40명의 안압을 측정하였다. 트리암시놀론 0.1 ml 주입군(0.1 IVTA군), 베바시주맙 0.05 ml 주입군(0.05 IVB군), 베바시주맙 0.1 ml 주입군(0.1 IVB군) 3집단으로 나눈 후 집단 간과 집단 내에서 주입술 전, 술 후 1일, 술 후 30일의 안압을 비교하였다. 결과: 집단 내 비교에서 0.05 IVB군과 0.1 IVB군에서는 주입 전 안압에 비해 주입 후 1일 안압이 유의하게 낮았으며(P＜0.001, P=0.035), 주입 후 30일에는 주입 후 1일에 비해 유의하게 상승한 결과를 보였다. 0.1 IVTA군의 경우 주입 전에 비해 주입 후 30일에 안압이 유의하게 상승하였다. 집단 간 비교에서는 시술 후 1일째 0.05 IVB군이 0.1 IVTA군보다 유의한 안압 저하를 보였다. 결론: 0.05 IVB군과 0.1 IVB군은 주입술 시행 후 1일에는 안압이 낮아지고 IVTA군은 술 후 30일에 유의한 안압상승을 보였다.
Abstract
Purpose: To compare intraocular pressure (IOP) changes after intravitreal triamcinolone acetonide versus bevacizumab injection. Methods: IOP was measured in 40 patients who received an intravitreal injection of 0.1 ml triamcinolone and 40 patients who received 2 consecutive intravitreal injections of bevacizumab (0.05 ml and 0.1 ml). Patients were divided into three groups : 0.1 ml triamcinolone group (0.1 IVTA group), 0.05 ml bevacizumab group (0.05 IVB group), and 0.1 ml bevacizumab group (0.1 IVB group). IOPs were compared within groups at different time points (before, 1 day after, and 30 days after the injection) and between groups at the same time points. Results: In the 0.05 IVB and 0.1 IVB groups, IOP at 1 day after injection was significantly lower than before injection (P＜ 0.01, P = 0.03), and IOP at 30 days after injection was significantly higher than IOP at 1 day after injection (P < 0.01, P < 0.01). In the 0.1 IVTA group, IOP at 30 days after injection was significantly higher than before injection (P = 0.01). Between groups, IOP at 1 day after injection in the 0.05 IVB group was significantly lower than IOP in the 0.1 IVTA group (P = 0.03). Conclusions: IOP was decreased at 1 day after intravitreal bevacizumab injection, whereas in intravitreal triamcinolone acetonide IOP elevation persisted after 1 month.
참고문헌 (40)
- Gordon MS, "Managing patients treated with bavacizumab combination therapy", Oncology, 69, pp.25~33 (2005)
- Gunther JB, "Bevacizumab (Avastin) for the treatment of ocular disease", Surv Ophthalmol, 54, pp.372~400 (2009)
- 김태환, "트리암시놀론 아세토나이드의 유리체강내 주사 농도에 따른 유리체강내의 잔류 기간 및 제거율 변화", 대한안과학회지, 46(9), pp.1569~1574 (2005), 대한안과학회
- Jermak CM, "Triamcinolone acetonide in ocular therapeutics", Surv Ophthalmol, 52, pp.503~522 (2007)
- Hollands H, "Short-term intraocular pressure changes after intravitreal injection of bevacizumab", Can J Ophthalmol, 42, pp.807~811 (2007)
- Falkenstein IA, "Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin)", Retina, 27, pp.1044~1047 (2007)
- Bakri SJ, "Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab", Eye, 23, pp.181~185 (2009)
- Özkiris A, "Complications of intravitreal injection of triamcinolone acetonide", Can J Ophthalmol, 40, pp.63~68 (2005)
- Jonas JB, "Intraocular pressure after intravitreal injection of triamcinolone acetonide", Br J Ophthalmol, 87, pp.24~27 (2003)
- 오민진, "유리체강내 트리암시놀론 주사 후 안압 상승에 대한 임상양상 분석", 대한안과학회지, 47(10), pp.1575~1582 (2006), 대한안과학회
- 이준목, "유리체강 내 트리암시놀론 아세토나이드 반복 주입술 후 안압 변화에 대한 추적 관찰 결과", 대한안과학회지, 48(1), pp.97~102 (2007), 대한안과학회
- Park HY, "Intravitreal pressure elevation after intravitreal triamcinolone acetonide injection", Korean J Ophthalmol, 19, pp.122~127 (2005)
- Ferrara N, "The biology of vascular endothelial growth factor", Endocr Rev, 18, pp.4~25 (1997)
- Adamis AP, "Angiogenesis and ophthalmic disease", Angiogenesis, 3, pp.9~14 (1999)
- Adamis AP, "The role of vascular endothelial growth factor in ocular health and disease", Retina, 25, pp.111~118 (2005)
- Kahook MY, "Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections", Ophthalmic Surg Lasers Imaging, 40, pp.293~295 (2009)
- Wiederholt M, "Dirtect involvement of trabecular meshwork in the regulation of aqueous humor outflow", Curr Opin Ophthalmol, 9, pp.46~49 (1998)
- Moncada S, "Nitric oxide: physiology, pathophysiology, and pharmacology", Pharmacol Rev, 43, pp.109~142 (1991)
- Bredt DS, "Nitric oxide: a physiologic messenger molecule", Annu Rev Biochem, 63, pp.175~195 (1994)
- Brüne B, "Nitric oxide and its role in apoptosis", Eur J Pharmacol, 351, pp.261~272 (1998)
- Schuman JS, "Nitrovasodilator effects on intraocular pressure and ocular facility in monkeys", Exp Eye Res, 58, pp.99~105 (1994)
- Wana RF, "Effect of the topical application of nitroglycerin on intraocular pressure in normal and glaucomatous monkeys", Exp Eye Res, 60, pp.337~339 (1995)
- Nathanson JA, "Alteration of ocular nitric oxide synthase in human glaucoma", Invest Ophthalmol Vis Sci, 36, pp.1774~1784 (1995)
- Matsuo T, "Basic nitric oxide production is enhanced by hydraulic pressure in cultured human trabecular cells", Br J Ophthalmol, 84, pp.631~635 (2000)
- Bouloumie A, "Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells", Cardiovasc Res, 41, pp.773~780 (1999)
- Dulak J, "Nitric oxide induces the synthesis of vascular endothelial growth factor by rat vascular smooth muscle cells", Arteioscler Thromb Vasc Biol, 20, pp.659~666 (2000)
- Wiederholt M, "Relaxation of trabecular meshwork and ciliary muscle by release of nitric oxide", Invest Ophthalmol Vis Sci, 35, pp.2515~2520 (1994)
- Spitzer MS, "Comparative antiproliferative and cytotoxic profile of bevacizuman (Avastin), pegaptanib (macugen) and ranibizumab (Lucentis) on different ocular cells", Graefes Arch Clin Exp Ophthalmol, 245, pp.1837~1842 (2007)
- Iriyama A, "Effect of anti-VEGF on retinal gangion cells in rats", Br J Ophthalmol, 91, pp.1230~1233 (2007)
- Bakri SJ, "Pharmacokinetics of intravitreal bevacizumab (Avastin)", Am J Ophthalmol, 114, pp.855~859 (2007)
- 김신후, "베바시주맙이 섬유주세포의 생존과 일산화질소의 생성에 미치는 영향", 대한안과학회지, 50(9), pp.1404~1408 (2009), 대한안과학회
- Krohne TU, "Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans", Am J Ophthalmol, 146, pp.508~512 (2008)
- Jones RF, "New method of measuring the rate of aqueous flow in man with fluorescein", Exp Eye Res, 5, pp.208~210 (1966)
- Polansky JR, "Cellular mechanisms influencing the aqueous humor outflow pathway", Ophthalmology, 94, pp.851~853 (1987)
- Parshley DE, "Early changes in matrix metalloproteinases and inhibitors after in vitro laser treatment to the trabecular meshwork", Curr Eye Res, 14, pp.537~544 (1995)
- Parshley DE, "Laser trabeculoplasty induced stromelysin expression by trabecular juxtacanalicular cells", Invest Ophthalmol Vis Sci, 37, pp.795~804 (1996)
- Kahook MY, "In vitro effects of antivascular endothelial growth factors on cultured human trabecular meshwork cells", J Glaucoma, 40, pp.63~68 (2010)
- 양연희, "유리체내 트리암시놀론 주사 후 안압의 변화", 대한안과학회지, 45(7), pp.1081~1085 (2004), 대한안과학회
- Jonas JB, "Intraocular pressure elevation after intravitreal triamcinolone acetonide injection", Ophthalmology, 112, pp.593~598 (2005)
- Rhee DJ, "Intraocular pressure alterations following intravitreal triamcinolone acetonide", Br J Ophthalmol, 90, pp.999~1003 (2006)